Comparative Clinical Pathology

, Volume 29, Issue 1, pp 47–52 | Cite as

Role of IL-6/IL-10 ratio in the diagnosis and in the assessment of the severity of obsessive-compulsive disorder

  • Marwa M. EsawyEmail author
  • Marwa A. Shabana
  • Eman F. Ali
Original Article


Obsessive-compulsive disorder (OCD) has a genetic and environmental pathogenesis. The immunologic changes in OCD have been proven in many studies, but those tackling cytokine in OCD are still limited. The present study aims to evaluate the diagnostic performance of IL-6, IL-10, and the IL-6/IL-10 ratio in the OCD patient group, and to show their correlation with the clinical parameters of OCD. Eighty subjects (60 OCD patients and 20 matched controls) were participating in this study. The enzyme-linked immunosorbent assay was run to quantify the IL-6 and IL-10. Serum IL-6 exhibited a higher result in OCD patients than controls (p = 0.002) but serum IL-10 levels had no significant difference (p > 0.05). IL-6/IL-10 ratio showed significantly higher values in OCD patients than controls (p < 0.0001). Serum IL-6 and IL-6/IL-10 ratio were negatively correlated with age of onset but were directly correlated with disease duration and disease severity. IL-6/IL-10 ratio showed 86.7% sensitivity and 90% specificity in OCD diagnosis. An immune activation is implicated in the OCD pathogenesis. This was confirmed by the high serum levels of IL-6 in OCD patients. IL-6/IL-10 ratio showed a considerable sensitivity and specificity in the OCD diagnosis. IL-6 and IL-6/IL-10 ratio are correlated positively with the OCD intensity.


Cytokine Interleukin-6, interleukin-10 OCD 



Area under the curve


Cerebrospinal fluid


Enzyme-linked immunosorbent assay




Negative predictive value


Obsessive-compulsive disorder


Positive predictive value


Receiver operating characteristic


Yale Brown Obsessive-Compulsive Scale


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Ethical Committee of the Faculty of Human Medicine, Zagazig University.

Informed consent

All study subjects were requested to participate, and they gave written informed consent.


  1. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, Burbaud P (2004) Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72:195–221. CrossRefPubMedGoogle Scholar
  2. Baganz NL, Blakely RD (2013) A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci 4(1):48–63. CrossRefPubMedGoogle Scholar
  3. Campos LM, Yoshimi NT, Simão MO, Torresan RC, Torres AR (2015) Obsessive-compulsive symptoms among alcoholics in outpatient treatment: prevalence, severity and correlates. Psychiatry Res 229(1–2):401–409. CrossRefPubMedGoogle Scholar
  4. Carpenter LL, Heninger GR, McDougle CJ, Tyrka AR, Epperson CN, Price LH (2002) Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Res 112(3):257–262. CrossRefPubMedGoogle Scholar
  5. Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H (2004) Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinol 29(7):945–952. CrossRefGoogle Scholar
  6. Elenkov IJ, Chrousos GP (2002) Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 966:290–303. CrossRefPubMedGoogle Scholar
  7. Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH (2013) Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 31:153–160. CrossRefPubMedGoogle Scholar
  8. Flament MF, Whitaker A, Rapoport JL, Davies M, Berg CZ, Shaffer D (1988) Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27(6):764–771. CrossRefPubMedGoogle Scholar
  9. Fluitman S, Denys D, Vulink N, Schutters S, Heijnen C, Westenberg H (2010) Lipopolysaccharide-induced cytokine production in obsessive-compulsive disorder and generalized social anxiety disorder. Psychiatry Res 178(2):313–316. CrossRefPubMedGoogle Scholar
  10. Gad SE, El Emshaty WM, Hussein HE, El-Borie OA, El-Hadid MA (2017) Early-onset versus late-onset obsessive–compulsive disorder: an immunological comparative study. Egyptian J Psych 38(1):41–48. CrossRefGoogle Scholar
  11. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989) The Yale-Brown obsessive compulsive scale. II Validity. Arch Gen Psychiatry 46(11):1012–1016. CrossRefPubMedGoogle Scholar
  12. Gray SM, Bloch MH (2012) Systematic review of proinflammatory cytokines in obsessive compulsive disorder. Curr Psychiatry Rep 14(3):220–228. CrossRefPubMedPubMedCentralGoogle Scholar
  13. Graybiel AM, Rauch SL (2000) Toward a neurobiology of obsessive-compulsive disorder. Neuron 28:343–347. CrossRefPubMedGoogle Scholar
  14. Koenig MK, Butler IJ (2011) Tetrahydrobiopterin deficiency. In: Gadoth N, Göbel H (eds) Oxidative stress and free radical damage in neurology. Oxidative stress in applied basic research and clinical practice. Humana Press, New York City, pp 225–234. CrossRefGoogle Scholar
  15. Konuk N, Tekın IO, Ozturk U, Atik L, Atasoy N, Bektas S, Erdogan A (2007) Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Med Inf 2007:65704–65705. CrossRefGoogle Scholar
  16. Lapidus KAB, Stern ER, Berlin HA, Goodman WK (2014) Neuromodulation for obsessive–compulsive disorder. Neurotherapeutics 11(3):485–495. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44(3):151–162. CrossRefPubMedGoogle Scholar
  18. Maes M, Meltzer HY, Bosmans E (1994) Psychoimmune investigation in obsessive-compulsive disorder: assays of plasmatransferrin, IL-2 and IL-6 receptor, and IL-1β and IL-6 concentrations. Neuropsychobiology 30(2–3):57–60. CrossRefPubMedGoogle Scholar
  19. Maina G, Pessina E, Albert U, Bogetto F (2008) 8-week single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment resistant obsessive–compulsive disorder. Eur Neuropsychopharmacol 18:364–372. CrossRefPubMedGoogle Scholar
  20. Marazziti D, Mucci F, Lombardi A, Falaschi V, Dell’Osso L (2015) The cytokine profile of OCD: pathophysiological insights. Int J Interferon Cytokine Mediat Res 7:35–42. CrossRefGoogle Scholar
  21. Milad MR, Rauch SL (2012) Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci 16(1):43–51. CrossRefPubMedGoogle Scholar
  22. Miller AH, Haroon E, Raison CL, Felger JC (2013) Cytokine target in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30:297–306. CrossRefPubMedPubMedCentralGoogle Scholar
  23. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159(6):2994–2999PubMedGoogle Scholar
  24. Monteleone P, Catapano F, Fabrazzo M, Tortorella A, Maj M (1998) Decreased blood levels of tumor necrosis factor alpha in patients with obsessive-compulsive disorder. Neuropsychobiology 37(4):182–185. CrossRefPubMedGoogle Scholar
  25. Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988–1000. CrossRefPubMedGoogle Scholar
  26. Murphy DL, Pigott TA (1990) A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. J Clin Psychiatry 51(4):53–58PubMedGoogle Scholar
  27. Murphy TK, Gerardi DM, Leckman JF (2014) Pediatric acute onset neuropsychiatric syndrome. Psychiatr Clin North Am 37:353–374. CrossRefPubMedGoogle Scholar
  28. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98:143–151. CrossRefPubMedGoogle Scholar
  29. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O (2013) Neuroinflammation and psychiatric illness. J Neuroinflammation 10:43. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Pauls DL (2010) The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci 12:149–163PubMedPubMedCentralGoogle Scholar
  31. Pittenger C, Bloch MH, Williams K (2011) Glutamate abnormalities in obsessive-compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 132:314–332. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Rao NP, Venkatasubramanian G, Ravi V, Kalmady S, Cherian A, Yc JR (2015) Plasma cytokine abnormalities in drug-naïve, comorbidity-free obsessive-compulsive disorder. Psychiatry Res 229(3):949–952. CrossRefPubMedGoogle Scholar
  33. Rodriguez CI, Kegeles LS, Levinson A, Ogden RT, Mao X, Milak MS, Vermes D, Xie S, Hunter L, Flood P (2015) In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive -compulsive disorder: proof of concept. Psychiatry Res Neuroimaging 233:141–147. CrossRefGoogle Scholar
  34. Russell A, Cortese B, Lorch E, Ivey J, Banerjee SP, Moore GJ, Rosenberg DR (2003) Localized functional neurochemical marker abnormalities in dorsolateral prefrontal cortex in pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13:31–38. CrossRefGoogle Scholar
  35. Schwartz M, Shaked I, Fisher J, Mizrahi T, Schori H (2003) Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 26:297–302. CrossRefPubMedGoogle Scholar
  36. Şimşek S, Yüksel T, Çim A, Kaya S (2016) Serum cytokine profiles of children with obsessive compulsive disorder shows the evidence of autoimmunity. Int J Neuropsychopharmacol 19(8):1–6. CrossRefGoogle Scholar
  37. Swedo ES (2012) From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Ther 2:113. CrossRefGoogle Scholar
  38. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP (2005) IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12(3):131–140. CrossRefPubMedGoogle Scholar
  39. Zohar AH (1999) The epidemiology of obsessive compulsive disorder in children and adolescents. Child Adolesc Psychiatr Clin North Am 8:445–460CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical Pathology, Faculty of Human MedicineZagazig UniversityZagazigEgypt
  2. 2.Department of Psychiatry, Faculty of Human MedicineZagazig UniversityZagazigEgypt

Personalised recommendations